NASDAQ:GTH - Genetron Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $19.50
  • Forecasted Upside: -22.16 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$25.05
▼ -1.78 (-6.63%)
1 month | 3 months | 12 months
Get New Genetron Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GTH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GTH

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$19.50
▼ -22.16% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Genetron in the last 3 months. The average price target is $19.50, with a high forecast of $20.00 and a low forecast of $19.00. The average price target represents a -22.16% upside from the last price of $25.05.
Buy
The current consensus among 2 polled investment analysts is to buy stock in Genetron.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/10/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/9/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/8/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/6/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/4/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/3/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/1/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/3/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/30/2020Canaccord GenuityReiterated RatingBuy$19.00High
i
7/14/2020Canaccord GenuityInitiated CoverageBuy$19.00High
i
7/14/2020BTIG ResearchInitiated CoverageBuy$20.00High
i
(Data available from 3/3/2016 forward)
Genetron logo
Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early liver cancer screening services through laboratory developed tests services, such as HCCscreen, a proprietary assay for the early screening of liver cancer. It also provides in-vitro diagnostics products, including 8-gene Lung Cancer Assay, an IVD assay product based on semiconductor sequencing to detect lung cancer; Genetron 3D biochip reading instrument; IDH1/TERT gene assays for glioma; GENETRON S5, a semiconductor sequencer used in the field of gene detection; and Genetron S2000 that enables gene panel sequencing. In addition, the company develops ctDNA Lung Cancer assay for mutations in the epidermal growth factor receptor gene. It also offers development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies, hospitals, and research institutions worldwide. The company has a partnership agreement with dMed Biopharmaceutical for new drug research and development in the field of oncology. The company was founded in 2015 and is headquartered in Beijing, the People's Republic of China.
Read More

Today's Range

Now: $25.05
$24.91
$27.01

50 Day Range

MA: $24.84
$17.39
$30.64

52 Week Range

Now: $25.05
$9.03
$31.54

Volume

141,347 shs

Average Volume

435,076 shs

Market Capitalization

$2.21 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Genetron?

The following sell-side analysts have issued research reports on Genetron in the last twelve months: BTIG Research, and Canaccord Genuity.
View the latest analyst ratings for GTH.

What is the current price target for Genetron?

2 Wall Street analysts have set twelve-month price targets for Genetron in the last year. Their average twelve-month price target is $19.50, suggesting a possible downside of 22.2%. BTIG Research has the highest price target set, predicting GTH will reach $20.00 in the next twelve months. Canaccord Genuity has the lowest price target set, forecasting a price of $19.00 for Genetron in the next year.
View the latest price targets for GTH.

What is the current consensus analyst rating for Genetron?

Genetron currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GTH will outperform the market and that investors should add to their positions of Genetron.
View the latest ratings for GTH.

What other companies compete with Genetron?

How do I contact Genetron's investor relations team?

Genetron's physical mailing address is 1-2/F BUILDING 11 ZONE 1 CHANGPING DISTRICT, BEIJING F4, 102206. The company's listed phone number is 86 10 5090 7500 and its investor relations email address is [email protected] The official website for Genetron is www.genetronhealth.com.